1. Home
  2. ELSE vs TVRD Comparison

ELSE vs TVRD Comparison

Compare ELSE & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electro-Sensors Inc.

ELSE

Electro-Sensors Inc.

HOLD

Current Price

$7.74

Market Cap

27.1M

Sector

Industrials

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.01

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELSE
TVRD
Founded
1968
2017
Country
United States
United States
Employees
N/A
12
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
27.5M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
ELSE
TVRD
Price
$7.74
$2.01
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
19.7K
2.9M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,142,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.20
N/A
52 Week Low
$4.10
$1.50
52 Week High
$7.75
$43.65

Technical Indicators

Market Signals
Indicator
ELSE
TVRD
Relative Strength Index (RSI) 72.24 37.48
Support Level $7.63 $1.50
Resistance Level $7.75 $4.32
Average True Range (ATR) 0.01 0.26
MACD -0.00 -0.09
Stochastic Oscillator 83.50 6.92

Price Performance

Historical Comparison
ELSE
TVRD

About ELSE Electro-Sensors Inc.

Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: